| P2093 | author name string | E Michael Lewiecki | |
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 |
| | Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 |
| | Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin | Q28295204 |
| | Denosumab in postmenopausal women with low bone mineral density | Q28298728 |
| | The long and the short of bone therapy | Q28298737 |
| | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 |
| | Osteoclast differentiation and activation | Q29547556 |
| | Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 |
| | Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. | Q31967823 |
| | Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling | Q34384039 |
| | Role of RANK ligand in mediating increased bone resorption in early postmenopausal women | Q34912769 |
| | Perspective. How many women have osteoporosis? | Q35437028 |
| | CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin | Q35597152 |
| | Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. | Q35848843 |
| | Pharmacokinetic aspects of biotechnology products | Q35856499 |
| | Antibody pharmacokinetics and pharmacodynamics | Q35897211 |
| | Assessment of fracture risk | Q35992561 |
| | Osteoclast precursors, RANKL/RANK, and immunology | Q36324916 |
| | The role of the immune system in the pathophysiology of osteoporosis | Q36324969 |
| | TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 |
| | A systematic review of persistence and compliance with bisphosphonates for osteoporosis | Q36739641 |
| | RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 |
| | Mortality after all major types of osteoporotic fracture in men and women: an observational study. | Q39490012 |
| | Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. | Q40263627 |
| | How many women have osteoporosis now? | Q40528035 |
| | Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation | Q40556337 |
| | The crippling consequences of fractures and their impact on quality of life | Q41597014 |
| | The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. | Q41649459 |
| | Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo | Q41753607 |
| | The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 |
| | Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin | Q43937881 |
| | Compliance with drug therapies for the treatment and prevention of osteoporosis | Q44256311 |
| | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 |
| | Compliance with pharmacologic therapy for osteoporosis | Q44593075 |
| | The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). | Q45105108 |
| | Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice | Q45874107 |
| | OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats | Q46099755 |
| | A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 |
| | Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial | Q46551911 |
| | Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. | Q46699294 |
| | Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses | Q46891798 |
| | Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). | Q46956288 |
| | Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism | Q47318126 |
| | Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice | Q47776871 |
| | The impact of compliance with osteoporosis therapy on fracture rates in actual practice | Q49211514 |
| | Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. | Q54043106 |
| | Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. | Q54137269 |
| | TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells | Q56975249 |
| | Costs Induced by Hip Fractures: A Prospective Controlled Study in Belgium | Q57415156 |
| | Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD | Q58971166 |
| | Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases | Q62392239 |
| | Fracture risk following an osteoporotic fracture | Q75202269 |
| | Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells | Q78181001 |
| | Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma | Q78835000 |
| | The effects of osteoprotegerin on the mechanical properties of rat bone | Q80528277 |
| | The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models | Q81300534 |
| | Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions | Q81388949 |
| P433 | issue | 4 | |
| P921 | main subject | osteoporosis | Q165328 |
| | postmenopausal osteoporosis | Q55950294 |
| P304 | page(s) | 645-653 | |
| P577 | publication date | 2008-12-01 | |
| P1433 | published in | Biologics: Targets and Therapy | Q4915042 |
| P1476 | title | Denosumab: an investigational drug for the management of postmenopausal osteoporosis | |
| P478 | volume | 2 | |